JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M909129199 on April 21, 2000

J. Biol. Chem., Vol. 275, Issue 26, 20217-20222, June 30, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/26/20217    most recent
M909129199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, X.
Right arrow Articles by Li, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, X.
Right arrow Articles by Li, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Macrophage-enriched Myristoylated Alanine-rich C Kinase Substrate and Its Phosphorylation Is Required for the Phorbol Ester-stimulated Diffusion of beta 2 Integrin Molecules*

Ximing ZhouDagger and Jianxun LiDagger §

From the Dagger  Department of Oral Biology, College of Dentistry and the § Department of Microbiology and Immunology, College of Medicine, University of Illinois, Chicago, Illinois 60612

Received for publication, November 11, 1999, and in revised form, April 13, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

An early event of beta 2 integrin activation is the increased diffusion rate of this molecule on the cell surface, thereby providing integrin molecules with a better chance to meet the ligands. The activation of protein kinase C (PKC) stimulates integrin diffusion by releasing the cytoskeletal constraint on integrin molecules. We report here that macrophage-enriched myristoylated alanine-rich C kinase substrate (MacMARCKS), a membrane-associated PKC substrate involved in integrin activation, is required for this PKC-stimulated diffusion of integrin molecules. Using the single-particle tracking technique, we observed that the activation of PKC stimulated an 11-fold increase in the diffusion rate of beta 2 integrins in wild type J774 macrophage cells but not in those expressing mutant MacMARCKS. Further evidence is provided from a MacMARCKS-deficient cell line in which phorbol esters failed to stimulate the diffusion of integrin. Transfection of wild type MacMARCKS into these cells restored the rapid diffusion rate of the beta 2 integrins. The phosphorylation of MacMARCKS is important because transfection of a nonphosphorylatable MacMARCKS mutant or the addition of staurosporine eliminates the rapid diffusion rate of integrin. Furthermore, adding cytochalasin D bypasses the MacMARCKS deficiency and stimulates beta 2 integrin diffusion, suggesting that MacMARCKS's involvement in integrin activation is prior or at the site of cytoskeleton. Therefore, we conclude that MacMARCKS is required for releasing the cytoskeletal constraint on integrin molecules during PKC-mediated integrin activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Integrin is a large family of adhesion molecules involved in many physiological processes, ranging from normal developmental processes to pathological processes such as tumor growth and inflammation (for review, see Refs. 1-4). Among the integrins, the beta 2 family is found exclusively in hemopoietic cells, and its activation, i.e. binding to its ligand, plays a vital role in immunological responses such as T cell activation (5), phagocytosis (6), and inflammation (7-9). A typical example of its role is the diapedesis of leukocytes. In its resting state, these immune cells do not adhere to the endothelium. Once stimulated, however, beta 2 integrin molecules on these cells show a high avidity toward the ligand on the epithelial cells of blood vessels, and the cells adhere firmly to endothelium (10, 11). Therefore, tight control of the activation process of beta 2 integrin is essential in regulating immune responses. Many substances can stimulate the activation of beta 2 integrin including chemokine, bacterial substance. Protein kinase C (PKC)1-mediated signal transduction pathway is very important for cell adhesion (12) and is essential for the activation of beta 2 integrin (for review, see Refs. 1, 2, 13, and 14), which is also part of the "inside-out" pathway. It has been suggested that the activation of PKC initiates either the conformation of integrin molecules to a high affinity state (15) or the clustering status of integrin molecules to obtain high avidity binding (16, 17).

Either way, the initial effect of PKC activation on integrin molecules is increased mobility of surface-bound beta 2 integrin molecules (18). This increased mobility results from an increase in random diffusion, not from an added external force. A similar increase in integrin diffusion also results from slightly depolymerizing the actin cytoskeleton, thereby suggesting that PKC-catalyzed phosphorylation actually causes the release of cytoskeletal constraints on integrin molecules (18). Such an increased lateral movement of beta 2 integrin molecules provides a better chance to meet ligands or to meet each other to form a cluster. Following the formation of a cluster, a firm link with the cytoskeleton is reestablished (19).

The question is: what proteins are responsible for translating the PKC signals to release the cytoskeletal constraint on integrin? MacMARCKS, a member of the MARCKS family of PKC substrates, is a macrophage-enriched myristoylated alanine-rich C kinase substrate (20, 21) that is primarily found in hemopoietic cells and epithelia cells.2 Its myristoylated N-terminal membrane targeting domain together with the positively charged effector domain (20) in the middle of the protein facilitate its association with the plasma membrane (22, 23). Because the effector domain contains the PKC phosphorylation sites, the membrane association of this protein is regulated by PKC-mediated phosphorylation (24).

Recent functional studies have indicated that the MARCKS family of proteins is involved in cell spreading (25, 26). Our studies have shown that MacMARCKS affects J774 macrophage cell spreading, likely the result of its effect on the tyrosine phosphorylation of the focal adhesion protein paxillin and on the activation of beta 2 integrin (25). Recently, the involvement of MacMARCKS in beta 2 integrin activation was also demonstrated in cells deficient in both MARCKS and MacMARCKS expression (27). The question is how MacMARCKS is required for integrin activation.

The recent application of the single-particle tracking technique provides a new insight into lateral movement of the integrin molecule (18, 28). This technique, developed in the late 1980s, visualizes the receptor or motor movement by conjugating it with small particles (40-200 nm) (18, 28-32) and observing particle movement in living cells with video-enhanced contrast microscopy. The technique allows us to study the behavior of a small group of molecules at the nanometer spatial precision with 30-ms time resolution (33, 34). The recorded particle track (Fig. 1) can then be analyzed for its randomness or restrictions, and a diffusion coefficient can also be obtained. In many cases, cytoskeletal constraints on receptors have been observed (35-38). In terms of beta 2 integrin, Kucik et al. (18) showed that an important step in the PKC-stimulated integrin activation is the relaxation of cytoskeletal constraints on beta 2 integrin molecules. This observation provided a basis for the hypothesis that certain proteins may be required for transducing the PKC signal to the cytoskeleton.

Here we report that MacMARCKS is required for releasing cytoskeletal constraints on integrin, a process initiated by PKC activation. Either mutation or lack of MacMARCKS blocks the PKC-stimulated increase of integrin mobility. Such a block can be bypassed by adding cytoskeleton depolymerizing reagent, suggesting that MacMARCKS indeed regulates the cytoskeleton-integrin link.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- J774 cell and Wehi 274.1 cells were purchased from ATCC. Hybridoma HB 226, which produces hamster anti-mouse beta 2 integrin antibody (2E6) (39), was purchased from ATCC and was grown in serum-free medium from Life Technologies, Inc. After removing the hybridoma, we collected the antibody-containing supernatant and concentrated it for later use. Monoclonal anti-MHC II (M1/42) antibody was kindly provided by Dr. R. Steinman (Rockefeller University, New York, NY). The carboxylated fluorescent latex beads were purchased from Molecular Probe (catalog no. F-8811; 200 nm in size). Dulbecco's modified Eagle's medium and other cell culture media were purchased from Life Technologies, Inc. Phorbol 12-myristate 13-acetate (PMA), 1,2-dioctanoyl-sn-glycerol (DOG), cytochalasin D, nocodazole, neuraminidase X, and other routine chemicals were purchased from Sigma. Macrophage chemoattractant protein-1 (MCP-1) was purchased from R&D Systems (Minneapolis, MN).

Cell Preparation-- J774 cells, Wehi 274.1.7 cells, or mutated cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Before the experiment, 5 × 106 cells were washed with phosphate-buffered saline (PBS) once and then treated with neuraminidase X (1 milliunit in 3 ml of buffer containing 0.13 M NaCl, 0.05 M NaAc, pH 6.5) for 30 min. Then, 0.5 ml of the cell suspension was added to 2.5 ml of Hanks' solution and plated on an acid-washed coverslip coated with poly-L-lysine (18, 40).

Conjugation of Antibodies to the Fluorescent Latex Beads-- Antibody against beta 2 integrin (2E6) either in the form of whole antibody or Fab2 fragments at a concentration of 10 mg/ml was conjugated to the carboxylated beads as described by the manufacturer's instructions (Molecular Probes). Since no difference between Fab2-conjugated and whole antibody-conjugated beads was observed in our single-particle tracking (data not shown), the whole antibody-coated beads were used in most cases. In a glass tube, 100 µl of antibody or BSA were added to the reaction mixture containing 50 µl of MES (200 mM), 50 µl of H2O, and 200 µl of carboxylated latex beads and left at room temperature for 15 min. Then 2 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide were added to the tube, which was vortexed for 2 h at room temperature. At the end of 2 h, 450 µl of glycine (1 M, pH = 6.25) were added, and the tube was vortexed for an additional 30 min to terminate the reaction. The excess proteins were removed by dialyzing the reaction mixture in a dialyzing bag (Mr cut-off 300,000) against 1 liter of 50 mM MES (pH 6.0) overnight. The buffer was then changed to PBS by dialyzing the beads against 1 liter of PBS for another 4 h. The beads were stored at 4 °C in 1.5 ml of PBS containing 1% BSA and 0.02% azide.

Since the microbeads used here have autofluorescence, at the end of the experiments, the beads were illuminated for their fluorescence so that they would not be confused with the subcellular organelles (Fig. 1A).

Video Microscopy-- Cells were plated on poly-L-lysine-coated coverslips in a steel chamber and placed on a water-jacketed heating stage on a Zeiss Axiovert 100 microscope with minimum light to prevent "burning" the cells. On poly-L-lysine coated surfaces in the serum-free medium, all types of cells used in these report adhered and spread equally well (Fig. 1B), regardless the status of MacMARCKS protein in these cells. After the cells spread and clearly showed their lamellipodia, the anti-beta 2 integrin antibody (2E6)-conjugated beads were added at a concentration of 4-5 beads/cell. PMA (100 nM), DOG (20 µM), MCP-1 (40 ng/ml), or cytochalasin D (0.3 µg/ml) was added at the same time as the beads. Recording was started as soon as the 2E6-conjugated beads fell onto and bound to the cells and continued for 30 s. Although the larger latex beads could be phagocytosed by macrophages, the beads used here were not phagocytosed during the observation time judged by vertical imaging on confocal microscope. This is either because the beads are too small to cause phagocytic receptor aggregation or because the 30-s observation time is too short for macrophages to phagocytose them. Beads coated with BSA or antibody against MHC II were used as controls. Bead motion was observed using video-enhanced differential interference contrast microscopy. A CCD camera system (Optronic DE750) with digital contrast enhancement and a Pentium II 400-MHz computer with 384 MB of RAM recorded the beads' motion directly into RAM at 30 frames/s. For each track, a 36-s segment was recorded using PIXCI software (Epix Inc., Buffalo Grove, IL) and transferred later to the hard drive. Location of the beads was determined manually in each video frame for 15 s, i.e. 450 frames. As examples, tracks of 2E6-coated beads were shown for each type of cells used in this report in the presence and absence of PMA (Fig. 1B).


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 1.   A, autofluorescence of the latex beads distinguishes them from the intracellular organelles. B, left panel, all types of cells used in the experiments spread equally well on the poly-L-lysine-coated coverslips, with 2E6-coated fluorescent beads on their surfaces; right panel, sample tracks of 2E6-coated beads on each type of cells treated with (+PMA) or without (-PMA) of PMA. In this case, the position of particles during 15 s of motion (450 frames at 30 frames/s) was extracted and a line connecting these points was drawn.

Data Analysis-- For each track of a bead, the mean square displacement (MSD) for each time interval was calculated from the xy coordinates of the particles according to Equations 1-3 (for review see, Ref. 34) by programming a macro in SigmaPlot software.3
&rgr;x(n&Dgr;T)=<LIM><OP>∑</OP><LL>i=0</LL><UL>N</UL></LIM>(x<SUB>i+n</SUB>−x<SUB>i</SUB>)<SUP>2</SUP>/(N+1) (Eq. 1)

&rgr;y(n&Dgr;T)=<LIM><OP>∑</OP><LL>i=0</LL><UL>N</UL></LIM>(y<SUB>i+n</SUB>−y<SUB>i</SUB>)<SUP>2</SUP>/(N+1) (Eq. 2)

<UP>MSD<SUB>total</SUB></UP>=&rgr;<SUB>n</SUB>=&rgr;(n&Dgr;T)=&rgr;x(n&Dgr;T)+&rgr;y(n&Dgr;T) (Eq. 3)
The obtained MSD is the sum of the random and directed motion.
<UP>MSD<SUB>total</SUB></UP>=<UP>MSD<SUB>random</SUB></UP>+<UP>MSD<SUB>directed</SUB>,</UP> (Eq. 4)
because
<UP>MSD<SUB>random</SUB></UP>=4Dt (Eq. 5)

<UP>MSD<SUB>directed</SUB></UP>=(&ngr;t)<SUP>2</SUP>. (Eq. 6)
Thus, we obtain Equation 7.
<UP>MSD<SUB>total</SUB></UP>=4Dt+(&ngr;t)<SUP>2</SUP> (Eq. 7)
By fitting the MSD calculated from the experimental data to the quadratic equation (Equation 7) using the SigmaPlot software, the diffusion coefficient D can be extracted.

Protein Phosphorylation-- Protein phosphorylation in vector- or MacMARCKS-transfected cells was determined by prelabeling cells with 32P-labeled inorganic phosphate (200 µCi) for 1 h in phosphate-free Dulbecco's modified Eagle's medium containing 10% dialyzed fetal bovine serum. After adding PMA (100 ng/ml), the cells were lysed in the lysis buffer (20), and MacMARCKS protein was immunoprecipitated with polyclonal anti-MacMARCKS antibody (41). The immunoprecipitant was then subjected to SDS-polyacrylamide gel electrophoresis and autoradiography.

Two-dimensional Phosphopeptide Mapping-- The gel slice containing MacMARCKS band was excised from the fully destained SDS gel and was washed with 50% methanol for at least 12 h. After drying with SpeedVac, the gel slice was incubated in 750 µl of 50 mM NH4HCO3 containing 100 µg/ml thermolysin and trace of phenol red at 37 °C for 16-18 h. The supernatant containing phosphopeptides was then collected and lyophilized in SpeedVac. The residues were redissolved in 10 µl of electrophoresis buffer (10% acetic acid, 1% pyridine), spotted on phosphocellulose plate (plastic back, Eastman Kodak Co.), and electrophoresis run at 400 V for 40 min in one dimension. The phosphocellulose plate was air-dried, and then chromatography was run in pyridine:n-butyl alcohol:HAc:H2O (15:10:3:12) on the other dimension. After air-drying, the plate was exposed to the film.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MacMARCKS Mutation Inhibits the PMA-stimulated Increase in the Random Diffusion of beta 2 Integrin in J774 Macrophage Cells-- To determine whether MacMARCKS mediates PKC's effect on the cytoskeletal constraint on integrin, we first examined the effect of the MacMARCKS mutation on the diffusion rate of the beta 2 integrin in J774 macrophage cells. J774 macrophage cells express endogenous wild type MacMARCKS, and their beta 2 integrin molecules can be activated by adding PMA, which activates PKC (25). We previously showed that expression of the effector domain deletion mutant of MacMARCKS in these cells blocks PMA-stimulated beta 2 integrin activation (25). Therefore, we tested whether this mutant affects the increased mobility of integrin in the initial steps of integrin activation.

We first measured the diffusion of beta 2 integrin of the wild type J774 cells before and after PMA treatment and compared it with that obtained from a B cell line by Kucik et al. (18). In agreement with their report, we, too, observed an approximately 11-fold increase in the diffusion rate of beta 2 integrin molecules after adding PMA to the wild type J774 cells that were transfected with empty vector as control (Fig. 2). For comparison, we examined the diffusion rate of beta 2 integrin molecules in J774 cells expressing the effector domain deletion mutant of MacMARCKS, the expression of which blocks activation of beta 2 integrin in these cells (25). Differing from the control J774 cells, no PMA-stimulated increase of integrin diffusion was seen in these mutant J774 cells (Fig. 2). Although the diffusion rate appeared slightly higher in unstimulated MacMARCKS mutant cells than that of unstimulated wild type cells, statistical analysis showed that this difference is not significant. In addition to PMA, DOG, another PKC activator, was also tested and a similar effect on integrin mobility was observed. Same as in the case of PMA, MacMARCKS mutation also blocked the increase in the mobility of beta 2 integrin stimulated by DOG (Fig. 2). These data coincide with the inhibitory effect of this mutant on the activation of beta 2 integrin (25), suggesting that MacMARCKS is likely involved in the initial step of beta 2 integrin activation, i.e. the releasing of integrin molecules from cytoskeletal constraint. This MacMARCKS effect appears not to be universally applied to all receptors. MHC II, another membrane protein with alpha beta dimeric structure, showed very little change in its mobility in respond to PMA treatment. MacMARCKS mutation did not alter its mobility neither (Fig. 2). As negative control, the movement of BSA-coated beads was also recorded. Similar to previous reports, we too showed that the BSA beads were basically immobile and its diffusion coefficient is far smaller (~10-12) than that of beta 2 integrin and MHC II.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   PMA, DOG, and MCP-1 stimulate the diffusion rate of beta 2 integrin, and MacMARCKS mutation blocks such an increase. A, a plot of MSD versus time of a 2E6-coated bead on vector-transfected control J774 cells (VEC) and J774 cells expressing the effector domain deletion mutant of MacMARCKS (ED) in the presence of PMA. The calculation was described under "Experimental Procedures." B, bar graph shows the mean and standard deviation of the diffusion coefficient (D) in both types of J774 cells and without or with the addition of PMA, DOG, and MCP-1. J774 minus PMA, D = 0.74 ± 0.19 × 10-10; J774 plus PMA, D = 8.10 ± 1.52 × 10-10; J774 plus DOG = 7.99 ± 1.43 × 10-10; J774 plus MCP-1 = 6.54 ± 2.05 × 10-10; ED minus PMA, 1.92 ± 0.38 × 10-10; ED plus PMA: 1.50 ± 0.15 × 10-10; ED plus DOG = 0.29 ± 0.19 × 10-10; ED plus MCP-1 = 0.46 ± 0.24 × 10-10. C, in addition, the diffusion coefficient of MHC II in both wild type and mutant cells stimulated with PMA are also shown: J774 minus PMA = 9.99 ± 1.57 × 10-10; J774 with PMA = 10.87 ± 2.15 × 10-10; ED with PMA = 11.21 ± 2.23 × 10-10. The BSA-coated beads was included as negative control, and they were basically not moving diffusion coefficient at the range of 10-12 (data not shown).

In addition to the pharmaceutical reagents, we also tested MCP-1, a physiological stimulus that can activate PKC and beta 2 integrin. Our data showed that MCP-1 was also capable of inducing the increase in the mobility of beta 2 integrin molecules and MacMARCKS mutation again blocked the increase (Fig. 2).

Expression of Exogenous Wild Type MacMARCKS Restores beta 2 Integrin Mobility in MacMARCKS-deficient Macrophage Cell Line-- To further test the above conclusion, we chose a cell line, Wehi 274.1.7, that has undetectable amounts of MacMARCKS protein and whose beta 2 integrin cannot be activated by adding PMA (27). Our previous report showed that, when wild type MacMARCKS is expressed in these cells, the PMA-induced, beta 2 integrin-mediated adhesion to ICAM-1-coated surface is restored in these cells (27). Thus, this cell line is a very useful model for studying beta 2 integrin diffusion by using the single-particle tracking technique. We observed that, although the diffusion rate of the beta 2 integrins in the vector-transfected control Wehi cells is similar to that of resting J774 cells, the diffusion rate of the beta 2 integrins does not increase in response to PMA as in the J774 cells (Fig. 3). The data correspond to the inability of beta 2 integrin to bind ICAM-1 (27). The data further support the observation made by Kucik et al. that the increased diffusion of beta 2 integrin is closely correlated with beta 2 integrin-mediated adhesion (18). After wild type MacMARCKS is expressed in these cells, the diffusion rate of beta 2 integrin molecules increases approximately 11-fold to a level similar to that in PMA-treated J774 cells, even without adding PMA.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of MacMARCKS in Wehi 274.1.7 cells restored the rapid diffusion rate of beta 2 integrin. Deficient in MacMARCKS expression, beta 2 integrin in Wehi 274.1.7 cells showed a minimum diffusion rate (D = 0.46 ± 0.11 × 10-10) even with PMA stimulation (D = 0.68 ± 0.13 × 10-10). Introducing wild type MacMARCKS into these cells caused beta 2 integrin to move at a higher rate (D = 5.09 ± 1.25 × 10-10) in the absence of PMA treatment, a rate similar to that in the presence of PMA (D = 6.76 ± 1.78 × 10-10). Such a rapid diffusion rate can be abolished by adding 100 nM staurosporine (D = 0.37 ± 0.10 × 10-10). The beta 2 integrin in cells expressing the SA mutant of MacMARCKS also showed a low diffusion rate both without (D = 1.60 ± 0.35 × 10-10) or with (D = 1.99 ± 0.40 × 10-10) PMA.

We suspected that this spontaneous increase in diffusion rate without PMA may be due to the uncontrolled phosphorylation of the transfected MacMARCKS in Wehi cells as compared with the endogenous MacMARCKS in J774 cells. Therefore, we examined the basal phosphorylation level of MacMARCKS in Wehi cells. Although the phosphorylated MacMARCKS in untreated J774 cells was only 30% of that in the PMA-treated J774 cells, this ratio reached to 80% in Wehi cells (Fig. 4). To be sure that MacMARCKS is phosphorylated at its PKC sites, we also performed two-dimensional phosphopeptide mapping and found that only the previously identified PKC sites was heavily phosphorylated (Fig. 4) (20). These data showed that a higher percentage of the transfected MacMARCKS in Wehi cells was phosphorylated when compared with endogenous MacMARCKS in J774 cells. We thus speculate that this higher phosphorylation may be due to loose control of MacMARCKS phosphorylation in Wehi cells because MacMARCKS is exogenous transfected protein.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   MacMARCKS phosphorylation in Wehi 274.1.7 cells and in J774 cells without and with PMA. Top, the ratio of phosphorylated MacMARCKS in cells without and with PMA stimulation. Middle, the autoradiographs of the phosphorylated proteins on SDS gels (see "Experimental Procedures"). Wehi cells show much higher phosphorylation of MacMARCKS before PMA treatment. Bottom, the two-dimensional phosphopeptide maps of each of the phosphorylated band, indicating only the PKC sites were phosphorylated (for detailed reference of the sites, see Ref. 20).

MacMARCKS Phosphorylation Is Required for Integrin Mobility-- If the high diffusion rate of beta 2 integrin in MacMARCKS-transfected Wehi cells results from the high level of MacMARCKS phosphorylation, then adding staurosporine, which inhibits MacMARCKS phosphorylation, should eliminate the rapid diffusion rate of beta 2 integrin molecules. Fig. 3 confirms that adding 100 nM staurosporine indeed lowers the diffusion rate of beta 2 integrin in Wehi cells to the same level as in the unstimulated J774 cells. In addition, if our speculation is true, the cells expressing a nonphosphorylatable mutant of MacMARCKS should not have a rapid diffusion rate. The SA mutant of MacMARCKS was mutated at the phosphorylation sites (serine to alanine) (20) and therefore prevented MacMARCKS from being phosphorylated by PKC. Transfection of this mutant in Wehi cells indeed did not increase the mobility of beta 2 integrin before or after adding PMA, suggesting that phosphorylation is necessary for MacMARCKS to release the constraint on integrin.

It is important to note, however, that although wild type MacMARCKS is able to stimulate the integrin mobility without PMA stimulation in Wehi cells, it is insufficient to fully activate the cell to adhere to ICAM-1-coated surface until PMA is added (27). This is likely due to that the increased mobility is only a first step in cell adhesion. A successful adhesion would require the involvement of many more proteins, and some of those may also be regulated by the addition of PMA. Therefore, this observation indicates that MacMARCKS is an essential but not sufficient condition. The phosphorylation of other components stimulated by PMA may also be required to fully activate integrin.

Cytoskeleton Depolymerizing Reagents Overcome MacMARCKS Defects-- The above data suggest that MacMARCKS is involved in releasing the cytoskeletal constraint on integrin molecules. Either mutation or lack of MacMARCKS in these cells prevents releasing integrin from its cytoskeleton constraint. If this is true, then artificially breaking the cytoskeletal link between integrin and cytoskeleton should overcome the defect of MacMARCKS. Kucik et al. have shown that small concentrations of cytochalasin D, an actin-depolymerizing agent, can bypass the PKC requirement and directly break the cytoskeleton to promote integrin diffusion. Following this approach, we observed that, after adding 0.3 µg/ml cytochalasin D, both mutant J774 cells and the MacMARCKS-deficient Wehi cells presented highly motile integrin molecules (Fig. 5). The data show that defects caused by MacMARCKS deficiency indeed lie prior or on the cytoskeletal constraint on the integrin molecules.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Cytochalasin D at low concentration bypasses the MacMARCKS deficiency. The low diffusion rate due to the lack of MacMARCKS in Wehi cells (Wehi Vec, D = 0.46 ± 0.11 × 10-10) or MacMARCKS mutation in ED-J774 cells (D = 1.92 ± 0.38 × 10-10) was restored by adding 0.3 µg/ml cytochalasin D to D = 7.62 ± 1.80 × 10-10 in Wehi cells and to D = 4.33 ± 1.01 × 10-10 in ED-J774 cells.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ample evidence has suggested a model in which cytoskeleton restricts the mobility of receptors, including beta 2 integrin, on the cell surface (18, 35-38). Evidence suggests that PKC activation releases the cytoskeletal constraint on beta 2 integrin, and that getting free from cytoskeletal constraint and diffusing rapidly on the membrane surface is a key step in beta 2 integrin activation (18). Integrin has a better chance, then, of meeting and binding the multivalent ligand and then undergoing conformational changes to a high affinity state. Bound integrins become relatively stationary, and more integrin molecules join to form a large cluster. Under the cluster, a new and stronger cytoskeleton link forms and new signals are transduced (19). In accord with this model, we have shown that the beta 2 integrin in J774 cells, similar to that in the B cells (18), responds to PMA stimulation by increasing its lateral diffusion rate. We further found that MacMARCKS protein is required for this PMA-stimulated increase of integrin diffusion. Either mutation or lack of MacMARCKS blocks the PMA-stimulated increased diffusion. Such a loss of a rapid diffusion rate likely results from the inability of the cell to release the cytoskeletal constraint on beta 2 integrin molecules, because after cytoskeleton is artificially depolymerized, the cells can bypass the MacMARCKS deficiency. This observation indicates that the final target of MacMARCKS is likely to be the cytoskeleton, either directly or indirectly. What is also important is that MacMARCKS phosphorylation is required, because staurosporine inhibits MacMARCKS-dependent increase of the diffusion rate of beta 2 integrin. The nonphosphorylatable form of MacMARCKS is incapable of conferring an increased diffusion rate on Wehi cells. The data further suggest that MacMARCKS regulates the cytoskeletal constraint under the control of PKC.

We speculate that MacMARCKS may be a direct part of the cytoskeletal constraint. The MARCKS family was identified as cytoskeleton-associated protein in the beginning (for review, see Ref. 42). Our recent study shows that MacMARCKS associates with a subunit of dynactin, which is an important regulator of microtubule motor protein.4 However, MacMARCKS is unlikely to bind directly to beta 2 integrin, partly because efforts to explore such binding did not show positive results (data not shown). In addition, the fact that lacking MacMARCKS immobilizes the beta 2 integrin clearly excludes the possibility that MacMARCKS directly restricts integrin diffusion. Rather, we think MacMARCKS may merely regulate a complex of proteins that links beta 2 integrin to cytoskeleton. Such a complex of proteins may be the previously described cytoskeletal barriers adjacent to the membrane that limits integrin diffusion (35-38). We propose a model here in which this complex that affects beta 2 integrin diffusion may form with or without MacMARCKS. Only the unphosphorylated MacMARCKS may be incorporated into this barrier. PKC-mediated phosphorylation causes MacMARCKS to break the complex. Without MacMARCKS, this cytoskeletal link can still form but no longer can be broken by PKC. When exogenous MacMARCKS is expressed in Wehi cells, MacMARCKS is reintroduced into this cytoskeletal complex. Because exogenous MacMARCKS somehow is easily phosphorylated in Wehi cells, we observed that the cytoskeletal complex is not stable, and we suspect that this is the reason beta 2 integrin in these cells has a rapid diffusion rate even before PMA treatment. Inhibition of kinases by staurosporine or transfection of nonphosphorylatable mutants of MacMARCKS reduces integrin mobility, further supporting this notion. Currently, the key problem for the hypothesis is that a MacMARCKS-containing cytoskeletal complex that somehow links to beta 2 integrin have not been identified. Whether a link truly exists remains to be determined. However, it is certain now that one of the consequences of MacMARCKS mutation is the failure to release the cytoskeleton constraint on beta 2 integrin molecules, a finding supported by the fact that depolymerizing cytoskeleton can bypass MacMARCKS deficiency.

How MacMARCKS is involved in the beta 2 integrin activation process as a cytoskeleton constraint is not known. Several possibilities exist. MacMARCKS may behave like MARCKS, which attaches to the plasma membrane (43) and cross-links actin so that it may modulate the general fluidity of the membrane. However, in such cases, MacMARCKS would have an effect on all membrane-bound receptors. An explanation is needed for its selective effects on beta 2 integrin but not on MHC II molecules. Alternatively, the membrane-associated MacMARCKS may serve as an anchor for other MacMARCKS binding proteins that may be linked to integrin. The key to this alternative hypothesis is to find the links between MacMARCKS and integrins. If this is the case, then other MacMARCKS like proteins such as MARCKS and GAP-43 (44) would likely be specific for other surface receptors. In addition, whether tyrosine kinases, for example focal adhesion kinase (45, 46), are involved in this cytoskeletal constraint should also be examined.

    ACKNOWLEDGEMENTS

We greatly appreciate Dr. D. Kucik and Dr. E. J. Brown for their extensive help in setting up the single-particle tracking techniques in our laboratory and for intellectually stimulating discussions.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM 54715.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom all correspondence should be addressed: Dept. of Oral Biology, College of Dentistry, University of Illinois, 801 S. Paulina St., Chicago, IL 60612. Tel.: 312-996-3520; Fax: 312-996-6044; E-mail: jxli@uic.edu.

Published, JBC Papers in Press, April 21, 2000, DOI 10.1074/jbc.M909129199

2 J. Li, unpublished data.

3 The computer program created in our laboratory for use in SigmaPlot software is available to anyone upon request.

4 Yue, L., Lu, S., Garces, J., Jin, T., and Li, J. (May 25, 2000) J. Biol. Chem. 10.1074/jbc.M001845200.

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; DOG, 1,2-dioctanoyl-sn-glycerol; ED, effector domain deletion mutant of MacMARCKS; ICAM-1, intercellular adhesion molecule 1; MARCKS, myristoylated alanine-rich C kinase substrate; MacMARCKS, macrophage-enriched myristoylated alanine-rich C kinase substrate; MCP-1, macrophage chemoattractant protein-1; MES, 2-(N-morpholino)ethanesulfonic acid; MSD, mean square displacement; PBS, phosphate-buffered saline; PMA, phorbol 12-myristate 13-acetate; BSA, bovine serum albumin; MHC, major histocompatibility complex.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hynes, R. O. (1992) Cell 69, 11-25
2. Clark, E. A., and Brugge, J. S. (1995) Science 268, 233-239
3. Stewart, M., Thiel, M., and Hogg, N. (1995) Curr. Opin. Cell Biol. 7, 690-696
4. Varner, J. A., and Cheresh, D. A. (1996) Curr. Opin. Cell Biol. 8, 724-730
5. Dustin, M. L., and Springer, T. A. (1989) Nature 341, 619-624
6. Buyon, J. P., Abramson, S. N., Philips, M. R., Slade, S. G., Ross, G. D., Weissman, G., and Winchester, R. J. (1988) J. Immunol. 140, 3156-3160
7. Graham, I. L., Lefkowith, J. B., Anderson, D. C., and Brown, E. J. (1993) J. Cell Biol. 120, 1509-1517
8. Nathan, C., Srimal, S., Farber, C., Sanchez, E., Kabbash, L., Asch, A., Gailit, J., and Wright, S. D. (1989) J. Cell Biol. 109, 1341-1349
9. Kashishian, A., MacAuley, A., and Cooper, J. A. (1990) Oncogene 5, 1463-1470
10. Wallis, W. J., Beatty, P. G., Ochs, H. D., and Harlan, J. M. (1985) J. Immunol. 135, 2323-2330
11. Gladwin, A. M., Hassall, D. G., Martin, J. F., and Booth, R. F. (1990) Biochim. Biophys. Acta 1052, 166-172
12. Woods, A., and Couchman, J. R. (1992) J. Cell Sci. 101, 277-290
13. Springer, T. A. (1990) Nature 346, 425-434
14. Rosales, C., and Juliano, R. L. (1995) J. Leukocyte Biol. 57, 189-198
15. Lollo, B. A., Chan, K. W., Hanson, E. M., Moy, V. T., and Brian, A. A. (1993) J. Biol. Chem. 268, 21693-21700
16. Landis, R. C., Bennett, R. I., and Hogg, N. (1993) J. Cell Biol. 120, 1519-1527
17. McDowall, A., Leitinger, B., Stanley, P., Bates, P. A., Randi, A. M., and Hogg, N. (1998) J. Biol. Chem. 273, 27396-27403
18. Kucik, D. F., Dustin, M. L., Miller, J. T., and Brown, E. J. (1998) J. Clin. Invest. 97, 2139-2144
19. Yamada, K. M., and Miyamoto, S. (1995) Curr. Opin. Cell Biol. 7, 681-689
20. Li, J., and Aderem, A. (1992) Cell 70, 791-801
21. Blackshear, P. J., Verghese, G. M., Johnson, J. D., Haupt, D. M., and Stumpo, D. J. (1992) J. Biol. Chem. 267, 13540-13546
22. Mosior, M., and McLaughlin, S. (1991) Biophys. J. 60, 149-159
23. Vergeres, G., and Ramsden, J. J. (1998) Biochem. J. 330, 5-11
24. Kim, J., Blackshear, P. J., Johnson, J. D., and McLaughlin, S. (1994) Biophys. J. 67, 227-237
25. Li, J., Zhu, Z., and Bao, Z. (1996) J. Biol. Chem. 271, 12985-12990
26. Myat, M. M., Anderson, S., Allen, L. A., and Aderem, A. (1997) Curr. Biol. 7, 611-614
27. Yue, L., Bao, Z., and Li, J. (2000) Cell Adhes. Commun. 7, 355-366
28. Schmidt, C. E., Horwitz, A. F., Lauffenburger, D. A., and Sheetz, M. P. (1993) J. Cell Biol. 123, 977-991
29. Kucik, D. F., Elson, E. L., and Sheetz, M. P. (1999) Biophys. J. 76, 314-322
30. Gelles, J., Schnapp, B. J., and Sheetz, M. P. (1988) Nature 331, 450-453
31. Sheetz, M. P., Turney, S., Qian, H., and Elson, E. L. (1989) Nature 340, 284-288
32. Kucik, D. F., Elson, E. L., and Sheetz, M. P. (1990) J. Cell Biol. 111, 1617-1622
33. Kucik, D. F., Elson, E. L., and Sheetz, M. P. (1989) Nature 340, 315-317
34. Qian, H., Sheetz, M. P., and Elson, E. L. (1991) Biophys. J. 60, 910-921
35. Simson, R., Sheets, E. D., and Jacobson, K. (1995) Biophys. J. 69, 989-993
36. Sako, Y., and Kusumi, A. (1994) J. Cell Biol. 125, 1251-1264
37. Anderson, C. M., Georgiou, G. N., Morrison, I. E., Stevenson, G. V., and Cherry, R. J. (1992) J. Cell Sci. 101, 415-425
38. Wilson, K. M., Morrison, I. E., Smith, P. R., Fernandez, N., and Cherry, R. J. (1996) J. Cell Sci. 109, 2101-2109
39. Metlay, J. P., Witmer-Pack, M. D., Agger, R., Crowley, M. T., Lawless, D., and Steinman, R. M. (1990) J. Exp. Med. 171, 1753-1771
40. Wright, S. D. (1986) Methods Enzymol. 132, 204-221
41. Zhu, Z., Bao, Z., and Li, J. (1995) J. Biol. Chem. 270, 17652-17655
42. Aderem, A. (1992) Cell 71, 713-716
43. Arbuzova, A., Murray, D., and McLaughlin, S. (1998) Biochim. Biophys. Acta 1376, 369-379
44. Liu, Y., and Storm, D. R. (1990) Trends Pharmacol. Sci. 11, 107-111
45. Guan, J. L., and Shalloway, D. (1992) Nature 358, 690-692
46. Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Cell Sci.Home page
A. S. Ada-Nguema, H. Xenias, M. P. Sheetz, and P. J. Keely
The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLC{epsilon}
J. Cell Sci., April 1, 2006; 119(7): 1307 - 1319.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
M. Kim, C. V. Carman, W. Yang, A. Salas, and T. A. Springer
The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2
J. Cell Biol., December 20, 2004; 167(6): 1241 - 1253.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. W. Zimmerman, J. M. D. T. Nelissen, S. E. van Emst-de Vries, P. H. G. M. Willems, F. de Lange, J. G. Collard, F. N. van Leeuwen, and C. G. Figdor
Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKC{alpha} independently of Rho-like GTPases
J. Cell Sci., June 1, 2004; 117(13): 2841 - 2852.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. W. Feigelson, V. Grabovsky, R. Shamri, S. Levy, and R. Alon
The CD81 Tetraspanin Facilitates Instantaneous Leukocyte VLA-4 Adhesion Strengthening to Vascular Cell Adhesion Molecule 1 (VCAM-1) under Shear Flow
J. Biol. Chem., December 19, 2003; 278(51): 51203 - 51212.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
N. Ni, C. G. Kevil, D. C. Bullard, and D. F. Kucik
Avidity Modulation Activates Adhesion under Flow and Requires Cooperativity among Adhesion Receptors
Biophys. J., December 1, 2003; 85(6): 4122 - 4133.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Jongstra-Bilen, R. Harrison, and S. Grinstein
Fc{gamma}-receptors Induce Mac-1 (CD11b/CD18) Mobilization and Accumulation in the Phagocytic Cup for Optimal Phagocytosis
J. Biol. Chem., November 14, 2003; 278(46): 45720 - 45729.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
E. P. Wojcikiewicz, X. Zhang, A. Chen, and V. T. Moy
Contributions of molecular binding events and cellular compliance to the modulation of leukocyte adhesion
J. Cell Sci., June 15, 2003; 116(12): 2531 - 2539.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. A. Worthylake and K. Burridge
RhoA and ROCK Promote Migration by Limiting Membrane Protrusions
J. Biol. Chem., April 4, 2003; 278(15): 13578 - 13584.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Liu, B. R. Schwartz, J. Tupper, N. Lin, R. K. Winn, and J. M. Harlan
The GTPase Rap1 Regulates Phorbol 12-Myristate 13-Acetate-stimulated but Not Ligand-induced beta 1 Integrin-dependent Leukocyte Adhesion
J. Biol. Chem., October 18, 2002; 277(43): 40893 - 40900.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Jin and J. Li
Dynamitin Controls beta 2 Integrin Avidity by Modulating Cytoskeletal Constraint on Integrin Molecules
J. Biol. Chem., August 30, 2002; 277(36): 32963 - 32969.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Wang, H. Hayashi, R. Harrison, B. Chiu, J. R. Chan, H. L. Ostergaard, R. D. Inman, J. Jongstra, M. I. Cybulsky, and J. Jongstra-Bilen
Modulation of Mac-1 (CD11b/CD18)-Mediated Adhesion by the Leukocyte-Specific Protein 1 Is Key to Its Role in Neutrophil Polarization and Chemotaxis
J. Immunol., July 1, 2002; 169(1): 415 - 423.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Palmantier, M. D. George, S. K. Akiyama, F. M. Wolber, K. Olden, and J. D. Roberts
cis-Polyunsaturated Fatty Acids Stimulate {beta}1 Integrin-mediated Adhesion ofHuman Breast Carcinoma Cells to Type IV Collagen by Activating ProteinKinases C-{{epsilon}} and -{micro}
Cancer Res., March 1, 2001; 61(6): 2445 - 2452.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
L. Yue, S. Lu, J. Garces, T. Jin, and J. Li
Protein Kinase C-regulated Dynamitin-Macrophage-enriched Myristoylated Alanine-Rice C Kinase Substrate Interaction Is Involved in Macrophage Cell Spreading
J. Biol. Chem., July 28, 2000; 275(31): 23948 - 23956.
[Abstract] [Full Text] [PDF]